SRDX Stock Recent News
SRDX LATEST HEADLINES
Surmodics (SRDX) reports a solid fiscal fourth quarter top line on the back of robust segmental revenues.
Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.
Investors are optimistic about Surmodics' (SRDX) consistent efforts to boost R&D.
Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #Needham--SRDX, a provider of medical device and in vitro diagnostic technologies, announced management will participate in upcoming investor conferences.
Surmodics, Inc. (NASDAQ:SRDX ) Q3 2023 Earnings Conference Call August 2, 2023 8:00 AM ET Company Participants Gary Maharaj - President & Chief Executive Officer Timothy Arens - Chief Financial Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Michael Matson - Needham & Company Michael Petusky - Barrington Research James Sidoti - Sidoti & Company Operator Welcome everyone to Surmodics Third Quarter of Fiscal Year 2023 Earnings Call. Please note that this call is being webcast.
Surmodics (SRDX) reports a solid fiscal third quarter top line on the back of robust Medical Device revenues.
The headline numbers for SurModics (SRDX) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
SurModics (SRDX) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of a loss of $0.46 per share. This compares to loss of $0.34 per share a year ago.
Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.